Keyphrases
COVID-19
100%
Patients with Cancer
59%
Overall Survival
34%
Chemotherapy-induced Peripheral Neuropathy
26%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
26%
Single nucleotide Variant
25%
Bortezomib
24%
COVID-19 Impact
24%
NCCTG
24%
Disease Genes
24%
Antibiotic Exposure
24%
Paclitaxel-induced Peripheral Neuropathy
24%
Small Intestinal Neuroendocrine Tumors
24%
COVID-19 Inpatients
24%
COVID-19 Severity
23%
Body Mass Index
20%
Immune Checkpoint Inhibitors
19%
Risk Factors
18%
Clinical Outcomes
18%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
18%
Chemotherapy
18%
Progression-free Survival
17%
Hospitalized Patients
15%
Registry-based
15%
Retrospective Cohort Study
15%
ARHGEF10
14%
Anticancer Treatment
14%
Tumor
14%
Non-small Cell Lung Cancer Patients
13%
Polyneuropathy
13%
30-day Mortality
13%
Immunosuppression
13%
Adjusted Odds Ratio
12%
Cancer Treatment
12%
Targeted Therapy
12%
Immune Checkpoint Blockade
12%
Myocardial Infarction
12%
Abiraterone
12%
Meta-analysis
12%
Non-linear Association
12%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
12%
Sarcoma
12%
Rodents
12%
Toxic Polyneuropathy
12%
Melanoma
12%
Consolidation Therapy
12%
Enzalutamide
12%
Venous Thromboembolism
12%
Prostate Cancer Patients
12%
Quality Assurance
12%
Medicine and Dentistry
COVID-19
85%
Malignant Neoplasm
74%
Non Small Cell Lung Cancer
38%
Immunotherapy
37%
Overall Survival
36%
Cohort Analysis
32%
Lung Cancer
24%
Neuroendocrine Tumor
24%
Breast Cancer
24%
Neoplasm
24%
Immune Checkpoint Inhibitor
21%
Progression Free Survival
18%
Cancer Therapy
18%
Body Mass Index
17%
Oncology
17%
Infection
15%
Immunosuppressive Treatment
14%
Retrospective Cohort Study
14%
Exome
14%
Monotherapy
12%
CDKN1B
12%
Predictor
12%
Coronavirinae
12%
Somatic Mutation
12%
Polyneuropathy
12%
Immune Checkpoint Blockade
12%
DeJerine-Sottas Disease
12%
Small Intestine
12%
Pancreas Islet Cell Tumor
12%
Cell Line
12%
Venous Thromboembolism
12%
Health Care
12%
Acute Myeloid Leukemia
12%
Connective Tissue Cancer
12%
Melanoma
12%
Cancer Treatment
10%
Neuroendocrine Tumor Cell Line
9%
Odds Ratio
9%
Cytokine Storm
7%
Logistic Regression Analysis
7%
Cancer Types
7%
Small Cell Lung Cancer
7%
Cancer
7%
Arterial Thromboembolism
6%
Pembrolizumab
6%
Cancer Cell
6%
All Cause Mortality
6%
Clinical Trial
6%
Targeted Therapy
6%
Chemotherapy-Induced Peripheral Neuropathy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
99%
Overall Survival
33%
Immunotherapy
32%
Cohort Study
29%
Non Small Cell Lung Cancer
26%
Immune Checkpoint Inhibitor
24%
Coronavirinae
24%
Lung Cancer
24%
Breast Cancer
24%
Progression Free Survival
20%
Neoplasm
19%
Diseases
16%
Infection
15%
Chemotherapy
14%
Enzalutamide
12%
Heart Infarction
12%
Abiraterone
12%
Prostate Cancer
12%
Cyclin Dependent Kinase Inhibitor 1B
12%
Neuroendocrine Tumor
12%
Afatinib
12%
Monotherapy
12%
Venous Thromboembolism
12%
Cisplatin
12%
Neurotoxicity
12%
Epidermal Growth Factor Receptor
12%
Bortezomib
12%
Acute Myeloid Leukemia
12%
Cerebrovascular Accident
12%
All Cause Mortality
10%
Chemotherapy-Induced Peripheral Neuropathy
9%
Cytokine Storm
7%
Mouse Strain
7%
Pembrolizumab
6%
Side Effect
5%
Clinical Trial
5%
Antibiotics
5%